{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:45:55Z","timestamp":1770453955056,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87506","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:25:47Z","timestamp":1751959547000},"source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune Hemolytic Anemia as an Initial Manifestation of Splenic Marginal Zone Lymphoma"],"prefix":"10.7759","author":[{"given":"Neeti","family":"Nachammai K M","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vengadakrishnan","family":"K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suja","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saajid","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont C","year":"2003","unstructured":"Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, Salles G, Berger F, Coiffier B. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003, 4:95-103. 10.1016\/s1470-2045(03)00981-1","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini L","year":"2016","unstructured":"Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016, 127:2072-81. 10.1182\/blood-2015-11-624312","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.011","article-title":"Autoimmune complications of chronic lymphocytic leukemia","volume":"33","author":"Hamblin TJ","year":"2006","unstructured":"Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006, 33:230-9. 10.1053\/j.seminoncol.2006.01.011","journal-title":"Semin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini W","year":"2020","unstructured":"Barcellini W, Fattizzo B. The changing landscape of autoimmune hemolytic anemia. Front Immunol. 2020, 11:946. 10.3389\/fimmu.2020.00946","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky RA","year":"2019","unstructured":"Brodsky RA. Warm autoimmune hemolytic anemia. N Engl J Med. 2019, 381:647-54. 10.1056\/NEJMcp1900554","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens H","year":"2013","unstructured":"Birgens H, Frederiksen H, Hasselbalch HC, et al.. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013, 163:393-9. 10.1111\/bjh.12541","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.743655","article-title":"Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States","volume":"54","author":"Liu L","year":"2013","unstructured":"Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma. 2013, 54:1380-6. 10.3109\/10428194.2012.743655","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Morton LM","year":"2014","unstructured":"Morton LM, Slager SL, Cerhan JR, et al.. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014, 2014:130-44. 10.1093\/jncimonographs\/lgu013","journal-title":"J Natl Cancer Inst Monogr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/aol-20-17","article-title":"The complex pathology and differential diagnosis of splenic and nodal marginal zone lymphoma","volume":"4","author":"Mollejo M","year":"2020","unstructured":"Mollejo M, Piris M. The complex pathology and differential diagnosis of splenic and nodal marginal zone lymphoma. Ann Lymphoma. 2020, 4:1-14. 10.21037\/aol-20-17","journal-title":"Ann Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage JO","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998, 16:2780-95. 10.1200\/JCO.1998.16.8.2780","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.03.005","article-title":"Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era","volume":"44","author":"Perrone S","year":"2016","unstructured":"Perrone S, D'Elia GM, Annechini G, Ferretti A, Tosti ME, Fo\u00e0 R, Pulsoni A. Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk Res. 2016, 44:53-60. 10.1016\/j.leukres.2016.03.005","journal-title":"Leuk Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2018.1500422","article-title":"Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma","volume":"8","author":"Oladiran O","year":"2018","unstructured":"Oladiran O, Dhital R, Donato A. Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma. J Community Hosp Intern Med Perspect. 2018, 8:244-5. 10.1080\/20009666.2018.1500422","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou AM","year":"2006","unstructured":"Tsimberidou AM, Catovsky D, Schlette E, et al.. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006, 107:125-35. 10.1002\/cncr.21931","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/382076-autoimmune-hemolytic-anemia-as-an-initial-manifestation-of-splenic-marginal-zone-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:25:48Z","timestamp":1751959548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/382076-autoimmune-hemolytic-anemia-as-an-initial-manifestation-of-splenic-marginal-zone-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.87506","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}